Collection: MEK1/2 targets
-
Bimetinib is a kinase inhibitor indicated in combination with encofenib for the treatment of patients with unresectable or metastatic melanoma whose tumors harbor BRAF V600E or V600K mutations as detected by an FDA-approved test.
Regular price ¥5,700.00 CNYRegular priceUnit price / per¥9,800.00 CNYSale price ¥5,700.00 CNYSale -
Binimetinib, MEKTODK, Binimetinib, 15mg
Regular price ¥3,500.00 CNYRegular priceUnit price / per¥6,000.00 CNYSale price ¥3,500.00 CNYSale -
TRAMAKS 2 Trametinib 2mg 30s
Regular price ¥900.00 CNYRegular priceUnit price / per¥1,500.00 CNYSale price ¥900.00 CNYSale -
Trametinib is indicated as a single agent or in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations.
Regular price ¥900.00 CNYRegular priceUnit price / per¥1,700.00 CNYSale price ¥900.00 CNYSale -
Trametinib, TRAMEDX, Trametinib 2mg
Regular price ¥1,200.00 CNYRegular priceUnit price / per¥1,800.00 CNYSale price ¥1,200.00 CNYSale